Clinically, high USP22 expression predicted poor prognosis for LT recipients with HCC beyond the Milan Criteria, and those patients could benefit the most from sirolimus, indicating that USP22 might serve as a proper stratification factor to give some advice for the clinical use of sirolimus in post‐LT management. The gene discussed is USP22; the disease is hepatocellular carcinoma.